Until now, the Shingrix vaccine against shingles, recommended since March 2024 for people aged 18 and over with a weakened immune system, as well as for people aged 65 and over, was available in community pharmacies but without be reimbursed. It has been reimbursed at 100% since May, but only at the hospital as part of a so-called direct access system, an advance treatment procedure for certain medications.
From now on, according to a decree published on Tuesday in the Official Journal, the vaccine from the British laboratory GSK against shingles will now be covered in France for the elderly and adults whose immune system is failing.
This health insurance coverage is intended for “the prevention of shingles and post-herpetic neuralgia in adults aged 65 and over, and adults aged 18 and over with an increased risk of shingles”, details the ‘stopped. “This step also means that community pharmacists, nurses and medical biologists will now be able to prescribe and administer Shingrix,” underlines the GSK laboratory in a press release.
Shingles is an infection that can affect anyone who has had chickenpox. It is due to the reactivation of the varicella-zoster virus, which can occur when the immune system is weakened due to, for example, illness, treatment (such as chemotherapy) or age, according to the High Authority health (HAS). The HAS concluded in March that “the effectiveness of the Shingrix vaccine was “much greater than that of the Zostavax vaccine” recommended since 2013 for the elderly.
Related News :